AGGRASTAT^®

Therapeutic Indication:

AGGRASTAT, in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events. AGGRASTAT is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

• Composition: Tirofiban as Hydrochloride Monohydrate 0.05 mg/ml.
• Pharmaceutical Form: Solution for Infusion.
• Method of Administration: Intravenous.
• How Supplied: Bag of 250 ml (12.5 mg).
• Manufacturer: Correvio International Sarl, Switzerland.